November 18, 2026
Health news, explained with evidence
LIVE
Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine

Investigational GLP-1 Antagonist Shows Promise for Post-Bariatric Hypoglycemia in Phase III Trial

❤️ Conditions & Care 2 min read 👁 3

Data from the phase III LUCIDITY trial indicate that the investigational agent avexitide significantly lowered the frequency of severe low blood sugar episodes in adults with post-bariatric hypoglycemia.

Investigational GLP-1 Antagonist Shows Promise for Post-Bariatric Hypoglycemia in Phase III Trial❤️Conditions & Care

Photo: medpagetoday.com

Key points

  • Investigational avexitide reduced hypoglycemic episodes in a phase III study.
  • The condition affects a subset of bariatric surgery patients due to exaggerated GLP-1 response.
  • Developers plan to pursue regulatory submission following the trial.

A recent phase III clinical trial presented at the ObesityWeek annual meeting highlights the potential of an investigational GLP-1 receptor antagonist to help individuals experiencing severe blood sugar drops following bariatric surgery. Researchers shared findings showing that daily administration of avexitide reduced weekly rates of moderate to severe hypoglycemic episodes compared to a placebo over a 16-week period.

Post-bariatric hypoglycemia is a challenging metabolic complication that can emerge months or years after procedures like Roux-en-Y gastric bypass. The condition involves heightened GLP-1 activity after eating, which triggers excessive insulin release and subsequent dangerously low blood glucose. Currently, no medications hold specific regulatory approval for this condition, meaning patients typically rely on strict carbohydrate restrictions and nutritional counseling to manage symptoms.

The LUCIDITY study evaluated 78 adult participants who maintained stable dietary interventions while receiving either subcutaneous injections of avexitide or a placebo. Investigators noted that while all participants received comprehensive dietary support and continuous glucose monitoring, those treated with the experimental therapy experienced a meaningful decrease in hypoglycemic events. Side effects were generally mild and centered around gastrointestinal symptoms or injection site reactions, with very few participants stopping treatment due to adverse events.

What to know

  • Treatment Focus: The trial tested avexitide for managing post-bariatric hypoglycemia, a condition marked by excessive insulin secretion after meals.
  • Study Design: The double-blind trial included 78 adults and compared once-daily injections against a placebo alongside standard dietary guidelines.
  • Safety Profile: Adverse effects were mostly mild to moderate, primarily involving gastrointestinal issues and mild injection-site reactions.

Patients experiencing symptoms of post-bariatric hypoglycemia should consult a qualified physician to discuss personalized dietary strategies and medical management options.

Source medpagetoday.com — medpagetoday.com/meetingcoverage/obesityweek/123896 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.